Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential

• Published in: Molecular neurodegeneration Vol. 18; no. 1; pp. 83 - 20
• Main Authors: Henrich, Martin T., Oertel, Wolfgang H., Surmeier, D. James, Geibl, Fanni F.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.11.2023; BioMed Central; BMC
• Subjects: Adenosine triphosphate; Antioxidants; Antioxidants - metabolism; Antioxidants - therapeutic use; Bioenergetics; Brain; Chelating agents; Clinical trials; Diabetes mellitus; Electron transport; Electron transport chain; Exenatide; Genotype & phenotype; Health aspects; Homeostasis; Humans; Liraglutide; Mitochondria; Mitochondria - metabolism; Mitochondrial dysfunction; Movement disorders; MPTP; Neurodegeneration; Neurodegenerative diseases; Neurons; Neurophysiology; Oxidative Stress; Parkinson Disease - metabolism; Parkinson's disease; Pathogenesis; Pathology; Quality control; Quality management; Synuclein; Transmitters; Antioxidants; Electron transport chain; Neuroprotective therapies; Mitochondria; Mitochondrial dysfunction; MPTP; Synuclein; Parkinson’s disease

Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD). However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants, antidiabetic drugs, and iron chelators, have failed in disease-modification clinical trial...